keyword
MENU ▼
Read by QxMD icon Read
search

PSA kinetics

keyword
https://www.readbyqxmd.com/read/29606109/neoadjuvant-degarelix-with-or-without-apalutamide-followed-by-radical-prostatectomy-for-intermediate-and-high-risk-prostate-cancer-arneo-a-randomized-double-blind-placebo-controlled-trial
#1
Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, Isabelle Salmon, Christine Decaestecker, Elai Davicioni, Christine Buerki, Frank Claessens, Johan Swinnen, Karolien Goffin, Raymond Oyen, Wouter Everaerts, Lisa Moris, Gert De Meerleer, Karin Haustermans, Steven Joniau
BACKGROUND: Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for early stage disease. Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor. The combination of apalutamide with degarelix, an LHRH antagonist, could increase the efficacy compared to degarelix alone...
April 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29508246/a-phase-ii-study-of-the-dual-mtor-inhibitor-mln0128-in-patients-with-metastatic-castration-resistant-prostate-cancer
#2
Laura Graham, Kalyan Banda, Alba Torres, Brett S Carver, Yu Chen, Katie Pisano, Greg Shelkey, Tracy Curley, Howard I Scher, Tamara L Lotan, Andrew C Hsieh, Dana E Rathkopf
Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castration-resistant prostate cancer (mCRPC). Methods Eligible patients had mCRPC previously treated with abiraterone acetate and/or enzalutamide. Five patients started MLN0128 at 5 mg once daily, subsequently dose reduced to 4 mg because of toxicity. Four subsequent patients started MLN0128 at 4 mg daily...
June 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29492810/comparison-of-choline-influx-from-dynamic-18-f-choline-pet-ct-and-clinicopathological-parameters-in-prostate-cancer-initial-assessment
#3
Xavier Palard-Novello, Anne-Lise Blin, David Bourhis, Etienne Garin, Pierre-Yves Salaün, Anne Devillers, Solène Querellou, Patrick Bourguet, Florence Le Jeune, Hervé Saint-Jalmes
AIM: The aim of the study was to compare the kinetic analysis of 18 F-labeled choline (FCH) uptake with static analysis and clinicopathological parameters in patients with newly diagnosed prostate cancer (PC). MATERIALS AND METHODS: Sixty-one patients were included. PSA was performed few days before FCH PET/CT. Gleason scoring (GS) was collected from systematic sextant biopsies. FCH PET/CT consisted in a dual phase: early pelvic list-mode acquisition (from 0 to10 min post-injection) and late whole-body acquisition (60 min post-injection)...
May 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29436189/prostate-specific-antigen-kinetics-following-5%C3%AE-reductase-inhibitor-treatment-may-be-a-useful-indicator-for-repeat-prostate-biopsy
#4
Ji Eun Heo, Kyo Chul Koo, Sung Joon Hong, Sang Un Park, Byung Ha Chung, Kwang Suk Lee
PURPOSE: To evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy. MATERIALS AND METHODS: From January 2007 to December 2015, patients who underwent a repeat prostate biopsy after an initial negative biopsy were enrolled from multiple institutions. Serial prostate-specific antigen (PSA) levels after the initial biopsy were analyzed for PSA kinetics. Clinicopathologic variables were evaluated according to the use of 5ARIs after the initial negative biopsy...
March 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29433975/refined-analysis-of-prostate-specific-antigen-kinetics-to-predict-prostate-cancer-active-surveillance-outcomes
#5
Matthew R Cooperberg, James D Brooks, Anna V Faino, Lisa F Newcomb, James T Kearns, Peter R Carroll, Atreya Dash, Ruth Etzioni, Michael D Fabrizio, Martin E Gleave, Todd M Morgan, Peter S Nelson, Ian M Thompson, Andrew A Wagner, Daniel W Lin, Yingye Zheng
BACKGROUND: For men on active surveillance for prostate cancer, utility of prostate-specific antigen (PSA) kinetics (PSAk) in predicting pathologic reclassification remains controversial. OBJECTIVE: To develop prediction methods for utilizing serial PSA and evaluate frequency of collection. DESIGN, SETTING, AND PARTICIPANTS: Data were collected from men enrolled in the multicenter Canary Prostate Active Surveillance Study, for whom PSA data were measured and biopsies performed on prespecified schedules...
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29425257/serum-prostate-specific-antigen-psa-concentration-psa-mass-and-obesity-a-mathematical-analysis
#6
Robin T Vollmer
Objectives: To provide a mathematical background for understanding the phenomenon of analyte hemodilution using a kinetic analysis. Methods: The first assumption for this analysis is that change in concentration of any analyte, such as prostate-specific antigen (PSA), is due to the flux of the analyte from an organ into the blood minus its flux from the blood. What results is a relatively simple differential equation that emphasizes the importance of plasma volume, organ mass, and two rate constants...
February 17, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29330943/epigenetic-markers-in-circulating-cell-free-dna-as-prognostic-markers-for-survival-of-castration-resistant-prostate-cancer-patients
#7
Rianne J Hendriks, Siebren Dijkstra, Frank P Smit, Johan Vandersmissen, Hendrik Van de Voorde, Peter F A Mulders, Inge M van Oort, Wim Van Criekinge, Jack A Schalken
BACKGROUND: Noninvasive biomarkers to guide personalized treatment for castration-resistant prostate cancer (CRPC) are needed. In this study, we analyzed hypermethylation patterns of two genes (GSTP1 and APC) in plasma cell-free DNA (cfDNA) of CRPC patients. The aim of this study was to analyze the cfDNA concentrations and levels of the epigenetic markers and to assess the value of these biomarkers for prognosis. METHODS: In this prospective study, patients were included before starting new treatment after developing CRPC...
April 2018: Prostate
https://www.readbyqxmd.com/read/29241329/epitope-binning-assay-using-an-electron-transfer-modulated-aptamer-sensor
#8
Min Li, Xudong Guo, Hui Li, Xiaolei Zuo, Rongzhang Hao, Hongbin Song, Ali Aldalbahi, Zhilei Ge, Jiang Li, Qian Li, Shiping Song, Shaohua Li, Ningsheng Shao, Chunhai Fan, Lihua Wang
Surface plasmon resonance and quartz crystal microbalance are workhorses of protein-DNA interaction research for over 20 years, providing ways to quantitatively determine the protein-DNA binding. However, the cost, necessary technical expertise, and severe nonspecific adsorption poses barriers to their use. Convenient and effective techniques for the measurement of protein-DNA binding affinity and the epitope binning between DNA and proteins for developing highly sensitive detection platform remain challenging...
January 10, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29190707/hypofractionated-stereotactic-boost-in-intermediate-risk-prostate-carcinoma-preliminary-results-of-a-multicenter-phase-ii-trial-ckno-pro
#9
David Pasquier, Philippe Nickers, Didier Peiffert, Philippe Maingon, Pascal Pommier, Thomas Lacornerie, Geoffrey Martinage, Emmanuelle Tresch, Eric Lartigau
PURPOSE: Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer. METHODS AND MATERIAL: Between August 2010 and April 2013, 76 patients with intermediated-risk prostate carcinoma were included in the study. A first course delivered 46 Gy by IMRT (68...
2017: PloS One
https://www.readbyqxmd.com/read/29153549/anticancer-activities-of-emetine-prodrugs-that-are-proteolytically-activated-by-the-prostate-specific-antigen-psa-and-evaluation-of-in-vivo-toxicity-of-emetine-derivatives
#10
Emmanuel S Akinboye, Marc D Rosen, Oladapo Bakare, Samuel R Denmeade
Emetine is a small molecule protein synthesis inhibitor that is toxic to all cell types and therefore suitable for complete killing of all types of heterogeneous cancer cells within a tumor. It becomes significantly inactive (non-toxic) when derivatized at its N-2' secondary amine. This provides a strategy for targeting emetine to cancerous tumor without killing normal cells. In this report, PSA activatable peptide prodrugs of emetine were synthesized. To overcome steric hindrances and enhance protease specific cleavage, a 2-stage prodrug activation process was needed to release emetine in cancer cells...
December 15, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29151227/significance-of-prostate-specific-antigen-kinetics-after-three-dimensional-conformal-radiotherapy-with-androgen-deprivation-therapy-in-patients-with-localized-prostate-cancer
#11
Wataru Fukuokaya, Sangji Kim, Takao Natsuyama, Kanako Matsuzaki, Homare Shiomi, Hiroki Kitoh, Nobuko Utsumi, Hiromasa Kurosaki, Masafumi Inoue, Koichiro Akakura
BACKGROUND: To evaluate the relationship between biochemical recurrence and post-radiation prostate-specific antigen (PSA) kinetics in patients with localized prostate cancer treated by radiotherapy with various durations of androgen deprivation therapy (ADT). METHODS: We reviewed our single-institution, retrospectively maintained data of 144 patients with T1c-T3N0M0 prostate cancer who underwent three-dimensional conformal radiotherapy (3D-CRT) between December 2005 and December 2015 and 113 patients were fulfilled the inclusion criteria...
November 18, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29149380/psa-kinetics-following-primary-focal-cryotherapy-hemiablation-in-organ-confined-prostate-cancer-patients
#12
Michael Kongnyuy, Shahidul Islam, Alfred K Mbah, Daniel M Halpern, Glenn T Werneburg, Kaitlin E Kosinski, Connie Chen, David J Habibian, Jeffrey T Schiff, Anthony T Corcoran, Aaron E Katz
PURPOSE: We aim to evaluate prostate-specific antigen (PSA) trends in post-primary focal cryotherapy (PFC) patients. MATERIALS AND METHODS: This was an institutional review board-approved retrospective study of PFC patients from 2010 to 2015. Patients with at least one post-PFC PSA were included in the study. Biochemical recurrence (BCR) was determined using the Phoenix criteria. PSA bounce was also assessed. We analyzed rates of change of PSA over time of post-PFC between BCR and no BCR groups...
February 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29090673/pet-ct-with-68ga-psma-in-prostate-cancer-radiopharmaceutical-background-and-clinical-implications
#13
Giampiero Giovacchini, Elisabetta Giovannini, Mattia Riondato, Andrea Ciarmiello
In the last twenty years, positron emission tomography / computed tomography (PET/CT) with radiolabeled choline, represented the most powerful imaging modality for prostate cancer (PCa). However, the low positive detection rate of the technique for PSA < 1 ng/ml prompted the development of other tracers for imaging PCa. 68Ga-PSMA is a receptor ligand tracer, which has been identified as the most promising radiopharmaceutical for imaging PCa. The most promising feature of this radiopharmaceutical is the high positive detection rate for prostate specific antigen (PSA) levels < 1 ng/ml or less (i...
November 1, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29040845/in-situ-regeneration-of-activated-carbon-with-electric-potential-swing-desorption-epsd-for-the-h-2-s-removal-from-biogas
#14
M Farooq, M N Almustapha, M Imran, M A Saeed, John M Andresen
In-situ regeneration of a granular activated carbon was conducted for the first time using electric potential swing desorption (EPSD) with potentials up to 30 V. The EPSD system was compared against a standard non-potential system using a fixed-bed reactor with a bed of 10 g of activated carbon treating a gas mixture with 10,000 ppm H2 S. Breakthrough times, adsorption desorption volume, capacities, effect of regeneration and desorption kinetics were investigated. The analysis showed that desorption of H2 S using the new EPSD system was 3 times quicker compared with the no potential system...
February 2018: Bioresource Technology
https://www.readbyqxmd.com/read/28887398/-64-cucl-2-pet-ct-in-prostate-cancer-relapse
#15
Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria
Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of 64 CuCl2 in humans and to assess the ability of 64 CuCl2 PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent 64 CuCl2 PET/CT, 18 F-choline PET/CT, and multiparametric MRI within 15 d of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated...
March 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864223/risk-factors-for-disease-progression-after-postprostatectomy-salvage-radiation-long-term-results-of-a-single-institution-experience
#16
Danielle Rodin, Michael Drumm, Rebecca Clayman, Daniela L Buscariollo, Sigolene Galland-Girodet, Alec Eidelman, Adam S Feldman, Douglas M Dahl, Francis J McGovern, Aria F Olumi, Andrzej Niemierko, William U Shipley, Anthony L Zietman, Jason A Efstathiou
BACKGROUND: Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing. PATIENTS AND METHODS: We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013...
August 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28816284/-predictive-factor-analysis-of-time-to-progression-of-castration-resistant-prostate-cancer-after-androgen-deprivation-therapy
#17
G J Ji, C Huang, G Song, X S Li, Y Song, L Q Zhou
OBJECTIVE: To explore risk factors including prostate-specific antigen (PSA) kinetics for the prediction of castration-resistant prostate cancer (CRPC), and to build a practical model for predicting the progression to CRPC after androgen deprivation therapy (ADT) so as to facilitate clinicians in decision-making for prostate cancer patients receiving ADT. METHODS: A total of 185 patients with prostate cancer who had received ADT as the primary therapy in Department of Urology of Peking University First Hospital from 2003 to 2014 were enrolled retrospectively...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28805875/frequency-selective-electrokinetic-enrichment-of-biomolecules-in-physiological-media-based-on-electrical-double-layer-polarization
#18
Ali Rohani, Bankim J Sanghavi, Armita Salahi, Kuo-Tang Liao, Chia-Fu Chou, Nathan S Swami
Proteomic biomarkers of interest to the early diagnosis of diseases and infections are present at trace levels versus interfering species. Hence, their selective enrichment is needed within bio-assays for speeding binding kinetics with receptors and for reducing signal interferences. While DC fields can separate biomolecules based on their electrokinetic mobilities, they are unable to selectively enrich biomarkers versus interfering species, which may possess like-charges. We present the utilization of AC electrokinetics to enable frequency-selective enrichment of nanocolloidal biomolecules, based on the characteristic time constant for polarization of their electrical double-layer, since surface conduction in their ion cloud depends on colloidal size, shape and surface charge...
August 24, 2017: Nanoscale
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#19
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28763873/-long-term-oncologic-outcomes-of-localized-high-risk-prostate-cancer-undergoing-brachytherapy-combined-with-external-beam-radiation-therapy-and-maximal-androgen-blockade
#20
Y Luo, M C Li, H Z Qi, J H Zhao, Y L Han, Y H Lin, Z Hou, Y G Jiang
Objective: To investigate the oncologic outcome and PSA kinetics of localized high-risk prostate cancer (PCa) patients treated with combination strategy of radiation therapy (RT) and maximal androgen blockade (MAB). Methods: We retrospectively reviewed the clinical data of 320 localized PCa patients undergoing RT+ MAB from 2001 to 2015. And radiation treatment protocol consisted of permanent prostate brachytherapy (PPB) at 110 Gy and EBRT at 45 Gy/23 fractions. Results: The median follow-up time was 90 (range: 12-186) months...
July 11, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
keyword
keyword
71305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"